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Unprovoked Seizures and Myoclonus 
in Patients with Alzheimer's Disease 
MARCIA L. MORRIS* 
ABSTRACT - Althou?h anecdotal references commonly presume that seizures eventually occur in patients 
affected with dementia of the Alzheimer type (OAT), no previous American study has documented 
the rate of new onset, unprovoked seizures in OAT patients. There are few documented cases of the occurrence 
of myo_clonus in autopsy-proven OAT. In a series of 83 autopsy-proven OAT cases, medical records were 
scrutinized for the presence of any seizure or myoclonic activity. Final evaluations were made by a neurologist. 
Of the 83 cases, 8 had experienced one or more unprovoked seizures after the onset of OAT. Based on 
age-specific incide_nce rates from a population study of Rochester, Minnesota, the expected number was 0.80 
Cp<.Ol). Eight patients developed myoclonus during the dementing illness. (No appropriate general popula-
tion study exists that would make comparison of rates of new onset myoclonus possible.) There was no overlap 
?et:-'~en tho~e who developed myoclonus and those who developed seizures. These data suggest that 
m?!Vlduals with OAT have a tenfold greater risk of developing seizures than an age-matched control, but that 
seizures cannot be considered a universal sign of OAT. Whether this increase in risk is uniform or whether 
seizures or myoclonus define unique subgroups of OAT types remains to be explored. ' 
Introduction 
Primary senile dementias have only come to be recognized 
as true disease states since 1956 when data from the National 
Institute of Mental Health (NIMH) Human Aging Study chal-
lenged the notion that "senility" was an inevitable result of 
normal aging ( 1,2). Neuropathological studies during the past 
15 years have now established that senile dementia of the 
Alzheimer type (SDAT) accounts for over 60% of the cases of 
primary dementia occurring in people over 65 (3). Alzhei-
mer's Disease is clinically and pathologically the same disease 
except that, by historic and arbitrary definition, onset occurs 
before age 65 (2,3,4). Unless specifically stated, Dementia of 
the Alzheimer's Type (DAT) will be used here to indicate all 
affected persons regardless of the age of initial onset. 
DAT victims progress from barely perceptible lapses in 
recent memory to increasingly handicapping and dehumaniz-
ing losses in judgment, emotionality, and physical function. 
This inevitably lethal decline is without remission and usually 
lasts for8 to lOyears after onset of symptoms. There is no cure, 
no effective treatment, and no practical, positive, pre-mortem 
diagnosis (4). 
Coupling these facts with current and projected numbers of 
cases, it is understandable that scientific interest in Alzhei-
mer's Disease is rapidly increasing. The proportion of older 
persons in the general population will continue to climb 
rapidly well into the 21st century, and it is this numerically 
increasing group that is at risk for DAT (Figure 1) (5). While 
there is as yet no definitive study of the prevalence or inci-
dence of DAT (6), it is estimated that DAT currently affects 
about 1.5 million people in the U.S. alone and causes or 
contributes to the death of 100 thousand older Americans per 
year (1,7). 
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The primary rationale for study of seizures in patients with 
DAT is two-fold. First, there is a clinical need for correct 
information. Scientitk literature and neurology textbooks 
commonly disagree on seizure rates. Some conclude that 
seizures are rare or unlikely. Meanwhile inferences are com-
monly made, both orally and in print, among both laypersons 
and clinical professionals, that seizures are so common in 
patients with Alzheimer's Disease that they may in fact be 
inevitable. Because many DAT patients and their loved ones 
find this prognosis especially anxiety provoking, any exagger-
ation of risk should not be viewed as harmless misinforma-
tion. Yet no previous American study has documented the rate 
of new onset, otherwise unprovoked seizures in patients 
affected with DAT (8). However, a Finish study of clinical 
findings in dementia noted that 6 out of 71 non-autopsy 
proven DAT cases had seizures (9). There are documented 
cases of the occurrence of myoclonus in autopsy proven DAT, 
but no appropriate age specific control rates are available for 
comparison (10,11). 
The second rationale involves basic scientific inquiry. 
Because secondary cases ofDAT are present in about 33% of 
the families located through one affected person (proband), 
both familial and sporadic cases appear to occur. The percen-
tage of familial cases rises to about 43% if only those probands 
who were affected before the age of 65 are considered (12). 
Any marker such as seizures or myoclonus occurring in one 
DAT group but not in another would be of interest, since such 
differences might signal different underlying biochemical or 
physiological changes. 
Methods 
Medical records, death certificates, and family interviews 
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Figure 1. Estimated number of Alzheimer's Disease cases, U.S., 
1900-2030. 
were scrutinized for an unselected series of83 probands with 
autopsy proven OAT who died in Minnesota state hospitals 
between 1952 and 1972. Any diagnosis of, or reference to, 
seizures or myoclonic activity were reviewed and classified by 
a neurologist. All of the seizure activity observed was of a 
generalized tonic-clonic nature, while a diagnosis of myoclo-
nus was made for cases exhibiting characteristic myoclonic 
shocklike or jerking movements involving only a subset of 
muscles. 
Using death and medical records as a source of data, like 
most archival types of research, can be criticized on several 
grounds: the amount of information available about the pro-
band varies, the cause of death listed may depend on the 
extent to which the person was studied medically before 
death, on the certifying physician's familiarity with the patient, 
and on whether or not an autospy was done; diagnostic 
labeling and reporting can vary from one area to another in 
medical practices. 
These shortcomings have been largely ameliorated in this 
study. The probands were all patients who had died in one of 
three Minnesota state hospitals during a discrete time period, 
which maximizes the homogeneity of the assessment and 
reporting methods used by the physicians and support per-
sonnel. Moreover, all 83 probands were autopsied, and full 
autopsy reports were available and studied. All medical 
information dating from the time of the probands' admission 
to the state hospitals until death, including reports of previous 
medical history, was available. This information was further 
amplified during field interviews with the probands' family 
members. 
Results 
Among the 83 OAT probands, 8 (9.6%) had seizures after 
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the onset of OAT. Three of these experienced single episodes, 
while 5 had recurrent seizures. Based on age-specific inci-
dence rates for combined single and multiple seizures from a 
population study of Rochester, Minnesota, the expected total 
is 0.80 (significant, p<. 01 , Poisson) ( 13). Another 2 probands 
experienced seizures before OAT onset, both having had 
seizures during childhood. This result is not significantly 
different from the .65 expected. A total of 8 probands expe-
rienced myoclonus after the onset of OAT. No cases of myoc-
lonus were recorded prior to OAT. Appropriate age-specific 
incidence rates for comparison are unavailable for myoclo-
nus. There is no overlap between those probands who expe-
rienced myoclonus and those who experienced seizures. 
The mean age ofOATonset was 71.3 for all 83 probands, 11 
of whom were determined to have had an onset prior to age 
65 (Table 1 ). Of the 11 with OAT onset prior to age 65, one had 
seizures and another had myoclonus (Table 2). The mean age 
of OAT onset was slightly lower in those who subsequently 
developed seizures (69 years) than the mean age for those 
who developed myoclonus (73.5 years). The mean age of 
seizure onset in those patients with OAT was 75.6 years, while 
the mean age for myoclonus onset was 79.5 years. The mean 
duration of illness in the OAT cases who developed seizures, 
9.1 years, was slightly longer than those who developed myoc-
lonus, 6.8 years; or neither, 8.3 years. The mean survivorship 
following onset of myoclonus was 1.1 years (Table 3 ). 
Table 1. Age distribution of Alzheimer's onset. 








Table 2. Myoclonus and seizures by age of Alzheimer's onset. 
Number of Persons in Interval 



















Table 3. Age at onset of DAT seizures, and myoclonus. 
Mean Age 
at Onset of 
Mean Age Seizures or Mean Age 
at DAT Onset Myoclonus at Death 
(Std. Dev.) (Std. Dev.) (Std. Dev.) 
DAT alone 71.3 79.6 
( 6.7) ( 6.0) 
DAT plus 69.0 75.6 78.1 
seizures ( 8.6) ( 8.0) ( 8.1) 
DAT plus 73.5 79.5 80.3 




These data suggest that individuals with OAT have a tenfold 
greater risk of developing seizures than an age-matched con-
trol, but that seizures cannot be considered a universal sign of 
DAT. Although the lack of an appropriate control study makes 
the absolute determination of the increased risk for myoclo-
nus impossible, the observed 9.6% who developed myoclo-
nus is probably a significant increase over an expected 
number. It is not clear whether these increases in risk are 
uniform or whether seizures or myoclonus occur only in 
unique subgroups ofDAT. In spite ofthe lowered OAT mean 
age of onset in prob~mds who developed seizures, the one 
incidence each of myoclonus and seizures in the group with 
DAT onset prior to age 65 tends to make this criteria an 
unlikely condition upon which to separate subgroups. Of 
more interest for continued research may be the lack of 
overlap between those probands who experienced myoclo-
nus and those who experienced seizures. 
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